Chloe Orkin on long-acting cabotegravir - a podcast by The Lancet HIV

Professor Chloe Orkin (Queen Mary University London, UK) joins Peter Hayward to talk about long-acting cabotegravir for HIV treatment and the 96 weeks of the FLAIR study.

Read the full article:
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30340-4/fulltext

Further episodes of The Lancet HIV in conversation with

Further podcasts by The Lancet HIV

Website of The Lancet HIV